金城医药(300233) - 金城医药调研活动信息

Company Overview - Shandong Jincheng Pharmaceutical Group Co., Ltd. was established in 2004 and listed on the Shenzhen Growth Enterprise Market in 2011, with a full industry chain from cephalosporin intermediates to specialty raw materials and finished formulations [3][4] - The company has over 20 subsidiaries and approximately 3,000 employees, with a steady growth in operating indicators, achieving a revenue of CNY 2.795 billion in 2019 [4] Financial Performance - In 2019, the company reported a total asset value of CNY 5.592 billion and paid taxes amounting to CNY 288 million, with a net profit of CNY 101 million in 2020 [4] Business Segments 1. Pharmaceutical Chemical Segment - This segment includes three wholly-owned subsidiaries, with over 30 products currently on sale and an average market share exceeding 60% for key products [4][5] - The segment has received national awards for technological advancements and is focused on continuous innovation to maintain its market leadership [4] 2. Biological Segment - The biological segment, primarily represented by Shandong Jincheng Biopharmaceutical Co., Ltd., has products like glutathione and adenosylmethionine, with a revenue of CNY 323 million and a net profit of CNY 95 million, showing a nearly 30% year-on-year growth [5] - The company holds over 80% of the global market share for glutathione raw materials, establishing itself as an industry leader [5] 3. Finished Formulations Segment - The finished formulations segment includes subsidiaries like Beijing Jincheng Tail Pharmaceutical Co., Ltd. and Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd. [5] - Key products include the immune modulator Pidotimod, which ranks first in market share, and the nitrofurantoin soft capsule, which has over 50% market share [5][6] Future Prospects - The company is expanding its product offerings, with new products like Cabergoline injection expected to receive approval by September or October 2020, and a focus on developing a raw material drug platform [7][8] - Plans are in place to build a high-standard raw material drug workshop compliant with FDA certification requirements, enhancing competitiveness in both domestic and international markets [8]